Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Augsburg
Clinical trial register · Germany

Clinical Trials in Augsburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5060 matching records held by the registry are in this view. Synced 14 Oct 2026, 03:18 UTC
5060
Studies in scope
all four open statuses
2879
Recruiting now
open to new participants
987
Lead sponsors
across recruiting studies
Top sites
Berlin 1589 Hamburg 891 Essen 764 Dresden 713 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 University Hospital Augsburg14 AbbVie7 Janssen Research & Development, LLC7 Novartis Pharmaceuticals7
Site location
Berlin1589 Hamburg891 Essen764 Dresden713 Heidelberg627
All 640 locations
Target enrolment
to

Trials with a site in Augsburg

251 of 5060 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
European Group for Research In Schizophrenia
Phase 3
171
Augsburg, Cologne, Mannheim, München
2027-01-01
Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
University of Oxford
Phase 3
250
Augsburg, Berlin, Cologne, Munich
2026-10-05
Not yet open
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
NCT07844057Small-bowel Adenocarcinoma, Metastatic Disease, Chemotherapy Effect
Annika Kurreck
Phase 2
86
Augsburg, Bad Saarow, Berlin, Chemnitz, Frankfurt, Herne, Landshut, München
2026-10-01
Not yet open
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors
NCT07762820Bladder Cancer, Bladder Cancer TNM Staging Primary Tumor (T) T1
Ludwig-Maximilians - University of Munich
Not applicable
75
Augsburg, Erlangen, Munich, Nuremberg
2026-09-01
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Not yet open
Women's Cancer Study Group GmbH
Phase 3
765
Heilbronn, Weinheim, Augsburg, München, Regensburg, Würzburg, Cottbus, Bad Nauheim
2026-08-30
Recruiting
John Neoptolemos
Phase 3
394
Aachen, Augsburg, Bochum, Bonn, Deggendorf, Dresden, Erlangen, Frankfurt
2026-08-17
Recruiting
Wuerzburg University Hospital
Not applicable
198
Augsburg, Erlangen, München, Regensburg, Würzburg
2026-07-24
Recruiting
Charite University, Berlin, Germany
Phase 3
320
Berlin, Augsburg, Frankfurt, Freiburg im Breisgau, Hamburg, Leipzig, München, Stralsund
2026-06-22
Not yet open
University Hospital Augsburg
Not applicable
100
Augsburg
2026-06-01
Recruiting
Philogen S.p.A.
Phase 2
180
Augsburg, Berlin, Essen, Halle, Kiel, Tübingen
2026-06-01
Recruiting
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
NCT07645443Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
Stephanie Mehl
Not applicable
252
Mannheim, Augsburg, München, Hamburg, Marburg, Cologne, Berlin
2026-05-27
Recruiting
AstraZeneca
Phase 3
670
Augsburg, Berlin, Bonn, Cologne, Dresden, Essen, Jena, Karlsruhe
2026-05-04
Recruiting
Women's Cancer Study Group GmbH
Phase 3
1,520
Mannheim, Tübingen, Esslingen am Neckar, Freiburg im Breisgau, Amberg, Augsburg, München, Würzburg
2026-04-29
Recruiting
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
NCT07788729Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
University of Regensburg
Not applicable
384
Augsburg, Erlangen, Regensburg, Würzburg, Bayreuth, Berlin, Cologne
2026-04-21
Recruiting
Novartis Pharmaceuticals
Observational
380
Baden-Baden, Heidenheim, Schwäbisch Hall, Winnenden, Aschaffenburg, Augsburg, Donauwörth, Herrsching am Ammersee
2026-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Augsburg, Munich, Jena, Berlin
2026-04-09
Not yet open
BCC-One-Stop-Study
NCT07482956Basal Cell Carcinoma
University Hospital Augsburg
Not applicable
290
Augsburg, Dresden, Erlangen, Munich
2026-04-01
Recruiting
Philipps University Marburg
Not applicable
3,369
Augsburg, Bad Neustadt an der Saale, Berlin, Cologne, Düsseldorf, Erlangen, Frankfurt, Giessen
2026-04-01
Recruiting
Subcutaneous Suture Versus no Subcutaneous Suture for Abdominal Wound Closure
NCT07615517Surgical Site Infection (SSI), Wound Healing Complication
University Hospital Augsburg
Not applicable
655
Augsburg
2026-03-23
Recruiting
Bristol-Myers Squibb
Phase 3
850
Augsburg, Erlangen, Koblenz, Ludwigshafen am Rhein, Magdeburg, Kiel, Jena, Berlin
2026-03-16
Recruiting
Medical University of Vienna
Observational
5,000
Augsburg, Würzburg, Berlin
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Augsburg, Bad Saarow, Berlin, Bonn, Dresden, Essen, Frankfurt, Freiburg im Breisgau
2026-02-03
Recruiting
Technische Universität Dresden
Phase 2
220
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald
2026-01-21
Recruiting
Celldex Therapeutics
Phase 3
240
Augsburg, Berlin, Buxtehude, Darmstadt, Dresden, Düsseldorf, Erlangen, Göttingen
2026-01-15
Recruiting
Eli Lilly and Company
Phase 3
150
Augsburg, Dresden, Hanover, München
2026-01-12
Recruiting
UNICANCER
Phase 3
3,902
Aachen, Augsburg, Bad Nauheim, Berlin, Bremen, Cottbus, Dresden, Düsseldorf
2025-12-18
Recruiting
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy
NCT07131956Prostate Cancer (Diagnosis), Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer Recurrent
University of Erlangen-Nürnberg Medical School
Observational
200
Augsburg, Erlangen, Munich
2025-12
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Augsburg, Hanover, Oberschleißheim
2025-11-25
Recruiting
Institut fuer Frauengesundheit
Not applicable
548
Augsburg, Erlangen, Hösbach
2025-11-04
Recruiting
Penumbra Inc.
Observational
200
München, Recklinghausen, Augsburg, Lübeck
2025-11-01
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Universität Münster
Phase 2
120
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Düsseldorf, Erlangen, Essen
2025-10-31
Recruiting
BioNTech SE
Phase 3
558
Augsburg, Bremen, Frankfurt, Freiburg im Breisgau, Gera, Hamburg, Koblenz, Mannheim
2025-10-30
Recruiting
Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
NCT07444801Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region
DrugTralokinumab
University Hospital Schleswig-Holstein
Observational
30
Augsburg, Lübeck
2025-10-20
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Recruiting
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
Jazz Pharmaceuticals
Phase 2
125
Augsburg, Hamburg, Witten
2025-09-24
Recruiting
Sanofi
Phase 3
942
Ahrensburg, Augsburg, Berlin, Darmstadt, Frankfurt, Frankfurt am Main, Hamburg, Leipzig
2025-09-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Esslingen am Neckar, Augsburg, München, Frankfurt am Main, Langen, Hanover, Düsseldorf, Essen
2025-09-11
Recruiting
AbbVie
Observational
2,795
Biberach an der Riss, Karlsruhe, Augsburg, Haßfurt, Kelheim, Kulmbach, Bramsche, Ahaus
2025-09-02
Recruiting
GlaxoSmithKline
Phase 3
420
Karlsruhe, Löwenstein, Stuttgart, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Lübeck
2025-08-11
Recruiting
AstraZeneca
Phase 3
700
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Düsseldorf, Essen
2025-08-06
Recruiting
Sanofi
Phase 3
723
Augsburg, Bielefeld, Dresden, Frankfurt, Freiburg im Breisgau, Hanover, Leipzig, Munich
2025-08-06
Recruiting
Celgene
Phase 3
400
Ulm, Augsburg, Göttingen, Dortmund, Düsseldorf, Münster, Homburg, Erfurt
2025-07-28
Recruiting
Michael Dill
Phase 2
48
Heidelberg, Augsburg, Essen, Mannheim, Regensburg, Tübingen, Ulm
2025-07-16
Recruiting
Galderma R&D
Observational
1,000
Karlsruhe, Langenau, Augsburg, Erlangen, Regensburg, Remscheid, Ahaus, Berlin
2025-07-14
Active, closed
Upstream Bio Inc.
Phase 2
666
Aschaffenburg, Augsburg, Bamberg, München, Cottbus, Hamburg, Darmstadt, Frankfurt am Main
2025-07-02
Recruiting
Sanofi
Observational
350
Auerbach, Augsburg, Bad Homburg, Berlin, Burgwedel, Darmstadt, Erkelenz, Flensburg
2025-07-01
Recruiting
MedSIR
Phase 2
200
Aschaffenburg, Augsburg, Dresden, Essen, Worms
2025-06-30
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Halle, Augsburg, Bad Bentheim, Berlin, Bielefeld, Bochum, Bramsche, Darmstadt
2025-06-27
Recruiting
AGO Research GmbH
Phase 2
42
Augsburg, Bad Homburg, Dresden, Düsseldorf, Essen, Göttingen, Hamburg, Hanau
2025-06-24
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Augsburg, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Hamburg, Heidelberg, Kiel
2025-06-04
Recruiting
Sanofi
Observational
150
Aschaffenburg, Augsburg, Dachau, Erlangen, Giessen, Wetzlar, Osnabrück, Weyhe-Kirchweyhe
2025-05-28
Recruiting
University Hospital Augsburg
Not applicable
100
Augsburg, Frankfurt am Main, Leipzig, Hamburg
2025-05-21
Recruiting
Apogee Therapeutics, Inc.
Phase 2
350
Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main, Bad Bentheim
2025-05-14
Recruiting
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Augsburg, Bad Bentheim, Berlin, Bonn, Bramsche, Darmstadt, Dresden, Friedrichshafen
2025-04-15
Recruiting
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
Study on Sex-specific, Individualized Dose Calculation of Contrast Agent in CT Examinations
NCT06965790CT Scans, Contrast Media, Gender, Womens Health
University Hospital Augsburg
Not applicable
400
Augsburg
2025-04-01
Recruiting
Resilience
Phase 3
1,458
Augsburg, Bad Saarow, Bochum, Hamburg, Hanover, Hösbach, Kiel, Lübeck
2025-04-01
Active, closed
Immutep S.A.S.
Phase 3
756
Amberg, Augsburg, Bad Saarow, Berlin, Cologne, Frankfurt, Frankfurt am Main, Gauting
2025-03-21
Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
NCT06925542SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
DrugZugo-cel
CRISPR Therapeutics
Phase 1
80
Augsburg, Cologne, Hanover, Mainz
2025-03-10
Recruiting
AbbVie
Phase 1/2
252
Freiburg im Breisgau, Heilbronn, Augsburg, Würzburg, Frankfurt am Main, Cologne, Hemer, Oldenburg in Holstein
2025-03-06
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
126
Aachen, Amberg, Augsburg, Bad Saarow, Berlin, Bielefeld, Chemnitz, Dortmund
2025-03-03
Recruiting
AstraZeneca
Phase 3
840
Augsburg, Bad Saarow, Berlin, Braunschweig, Chemnitz, Düsseldorf, Erlangen, Essen
2025-03-01
Recruiting
Technical University of Munich
Observational
94
Augsburg, Munich
2025-03
Recruiting
Central Institute of Mental Health, Mannheim
Not applicable
140
Aachen, Augsburg, Göppingen, Göttingen, Hanover, Heidelberg, Ingolstadt, Mainz
2025-02-14
Recruiting
Comprehensive Cancer Center Munich (CCCM)
Observational
80
Augsburg, Munich, Würzburg
2025-01-22
Recruiting
Lumbar Drainage of Intraventricular Hemorrhage
NCT06510842Intraventricular Hemorrhage, Lumbar Drainage, External Ventricular Drainage
University Hospital Heidelberg
Not applicable
354
Heidelberg, München, Augsburg, Berlin, Düsseldorf, Frankfurt, Göttingen, Mainz
2025-01-16
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Augsburg, Tübingen, Erlangen, Mahlow, Darmstadt, Frankfurt am Main, Bad Bentheim, Bramsche
2025-01-08
Recruiting
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
NCT06201234Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
DrugsElacestrant·Olaparib
GBG Forschungs GmbH
Phase 2
176
Stuttgart, Tübingen, Winnenden, Weinheim, Augsburg, Bayreuth, Fürstenwalde, Frankfurt am Main
2024-12-13
Recruiting
Pfizer
Phase 3
2,330
Munich, Frankfurt am Main, Obertshausen, Cologne, Augsburg, Berlin, Freiburg im Breisgau, Hamburg
2024-12-08
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
DrugsElacestrant·Everolimus
MedSIR
Phase 3
300
Aschaffenburg, Augsburg, Dessau, Düsseldorf, Essen, Georgsmarienhütte, Worms
2024-12-05
Recruiting
GBG Forschungs GmbH
Phase 2
120
Augsburg, Berlin, Bielefeld, Bremen, Cologne, Cottbus, Dortmund, Essen
2024-12-04
Recruiting
AbbVie
Observational
678
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Marktredwitz, Munich
2024-11-07
Recruiting
Goethe University
Phase 2
28
Augsburg, Berlin, Bremen, Dresden, Düsseldorf, Erlangen, Frankfurt am Main, Hamburg
2024-10-22
Active, closed
Eli Lilly and Company
Phase 2
143
Augsburg, Berlin, Brandenburg an der Havel, Duisburg, Frankfurt am Main, Halle, Hamburg, Hanover
2024-10-10
Recruiting
Women's Cancer Study Group GmbH
Phase 3
348
Baden-Baden, Böblingen, Freiburg im Breisgau, Heilbronn, Tübingen, Ulm, Weinheim, Augsburg
2024-10-10
Recruiting
iOMEDICO AG
Observational
100
Augsburg, Bad Liebenwerda, Bad Mergentheim, Berlin, Dresden, Essen, Hanover, Hof
2024-10-08
Active, closed
AstraZeneca
Phase 3
310
Augsburg, Bonn, Cottbus, Hanover, Mainz
2024-09-30
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Mannheim, Ulm, Augsburg, Eggenfelden, Erlangen, München, Regensburg, Rüdersdorf
2024-09-27
Recruiting
University Hospital Schleswig-Holstein
Phase 2/3
459
Kiel, Aachen, Augsburg, Bamberg, Berlin, Bremen, Cologne, Dachau
2024-09-12
Recruiting
Liquid Biopsy Under PSMA Radioligand Therapy
NCT07118436Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer
Wuerzburg University Hospital
Observational
100
Augsburg, München, Würzburg
2024-09-01
Active, closed
Regeneron Pharmaceuticals
Phase 4
120
Augsburg, Munich, Frankfurt am Main, Koblenz, Lübeck, Berlin, Leipzig, Mainz
2024-08-26
By invitation
University Hospital Augsburg
Not applicable
10
Augsburg
2024-08-13
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Augsburg, Frankfurt am Main, Lüneburg, Kiel, Freiburg im Breisgau
2024-08-07
Recruiting
Dr. Inge Winter
Phase 4
418
Augsburg, Bielefeld, Dortmund, Frankfurt am Main, Mainz, Münster
2024-08-01
Recruiting
AstraZeneca
Phase 3
788
Aachen, Augsburg, Berlin, Cologne, Dessau, Düsseldorf, Erlangen, Göttingen
2024-08-01
Recruiting
AstraZeneca
Observational
300
Ahrensburg, Ansbach, Aschaffenburg, Auerbach, Augsburg, Bad Homburg, Berlin, Cottbus
2024-07-25
Recruiting
Deutsches Herzzentrum Muenchen
Not applicable
666
Heidelberg, Mannheim, Singen, Ulm, Augsburg, Dachau, Erding, Ingolstadt
2024-07-01
Recruiting
A Registry-study of ELZONRIS in Participants With BPDCN
NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
DrugTagraxofusp
Stemline Therapeutics, Inc.
Observational
80
Augsburg, Bielefeld, Chemnitz, Frankfurt, Freiburg im Breisgau, Halle, Hamburg, Kiel
2024-06-26
Active, closed
Celgene
Phase 3
850
Ulm, Augsburg, Bayreuth, Erlangen, Langen, Hanover, Koblenz, Halle
2024-06-19
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Augsburg, Düsseldorf, Essen, Heidelberg, Lübeck
2024-05-15
Active, closed
Sanofi
Phase 3
1,541
Augsburg, Bad Bentheim, Hamburg, Kiel, Mainz, Münster, Witten
2024-05-08
Active, closed
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948Atopic Dermatitis
DrugAPG777
Apogee Therapeutics, Inc.
Phase 2
470
Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Blankenfelde-Mahlow, Darmstadt, Frankfurt am Main
2024-04-29
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
24
Augsburg, Berlin, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg, Hanover, München
2024-04-17
Active, closed
Janssen-Cilag Ltd.
Phase 3
120
Augsburg, Berlin, Dachau, Frankfurt, Göttingen, Halle, Hanover, Kiel
2024-04-17
Active, closed
Celldex Therapeutics
Phase 2
140
Augsburg, Bad Bentheim, Berlin, Bochum, Erlangen, Frankfurt, Heidelberg, Münster
2024-04-12
Active, closed
University Hospital Tuebingen
Phase 2
107
Augsburg, Cologne, Frankfurt, Freiburg im Breisgau, Leipzig, Mannheim, Munich, Regensburg
2024-04-10
Recruiting
Technische Universität Dresden
Phase 2
146
Essen, Aachen, Augsburg, Chemnitz, Cologne, Dresden, Erlangen, Frankfurt am Main
2024-04-07
Active, closed
University of Heidelberg Medical Center
Phase 3
411
Aachen, Augsburg, Bad Saarow, Berlin, Bielefeld, Bonn, Braunschweig, Chemnitz
2024-04-05
Recruiting
Seroma of the Mammary Gland
NCT05899387Seroma, Breast Cancer, Mastectomy, Breast Implant; Complications
University Hospital Augsburg
Not applicable
2,000
Augsburg
2024-04-01
Recruiting
GlaxoSmithKline
Phase 3
864
Augsburg, Berlin, Erlangen, Essen, Giessen, Hamburg, Neuruppin, Straubing
2024-03-21
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Munich, Cologne, Aachen, Augsburg, Berlin, Essen, Münster, Rostock
2024-03-12
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Augsburg, Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Dülmen, Düsseldorf
2024-03-09
Recruiting
Intraocular Lens Implant Registry Study
NCT06294405Intraocular Lens Complication, Intraocular Lens Rotation, Intraocular Lens Associated Postoperative Inflammation, Lens Opacities
University Hospital Augsburg
Observational
500
Augsburg
2024-02-21
Recruiting
AstraZeneca
Phase 3
5,250
Ahrensburg, Augsburg, Bamberg, Berlin, Bonn, Bremen, Cottbus, Dachau
2024-02-21
Recruiting
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT06134492Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia, Herpes Simplex
DrugAcyclovir
Jena University Hospital
Phase 3
616
Freiburg im Breisgau, Heidelberg, Tübingen, Augsburg, München, Nuremberg, Regensburg, Rosenheim
2024-02-20
Recruiting
Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients
NCT06279793Intensive Care Unit, Coronary Artery Bypass Grafting (CABG), High Risk Patients, Cardiopulmonary Bypass
GCP-Service International West GmbH
Phase 2
550
Augsburg, Berlin, Bonn, Göttingen, Hamburg, Kiel, Mainz, Münster
2024-02-15
Active, closed
AstraZeneca
Observational
111
Aschaffenburg, Augsburg, Bergisch Gladbach, Berlin, Bonn, Cologne, Dresden, Duisburg
2024-02-14
Active, closed
Boehringer Ingelheim
Phase 3
428
Augsburg, Berlin, Cologne, Dresden, Giessen, Heidelberg, Oldenburg, Tübingen
2024-02-09
Recruiting
Women's Cancer Study Group GmbH
Phase 2
702
Baden-Baden, Freiburg im Breisgau, Tübingen, Ulm, Augsburg, Munich, Bremerhaven, Frankfurt am Main
2024-02-05
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
NCT06835218Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
UroTrials Company (GmbH)
Observational
5,000
Freiburg im Breisgau, Heidelberg, Mannheim, Nürtingen, Tübingen, Ulm, Augsburg, Bayreuth
2024-01-29
Active, closed
Early Genetic Identification of Obesity
NCT06239064Obesity, Childhood, Hyperphagia, Retinopathy, Syndactyly
Rolfs Consulting und Verwaltungs-GmbH (RCV)
Observational
1,000
Aachen, Augsburg, Bad Krozingen, Bielefeld, Bonn, Bückeburg, Cologne, Essen
2024-01-24
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Augsburg, Halle, Heidelberg, Magdeburg, München, Tübingen, Würzburg
2024-01-22
Recruiting
University Hospital Augsburg
Observational
500
Augsburg
2024-01-01
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Heidenheim, Konstanz, Mannheim, Schorndorf, Stuttgart, Augsburg, Munich, Bremenhaven
2023-12-20
Recruiting
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
NCT05512364ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
220
Aachen, Augsburg, Bergisch Gladbach, Bottrop, Bremen, Cologne, Dresden, Hanover
2023-12-15
Active, closed
Nikolaj Frost MD
Phase 4
136
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Cologne, Dresden, Essen
2023-12-06
Active, closed
ACADIA Pharmaceuticals Inc.
Phase 3
170
Augsburg, Essen
2023-11-27
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Augsburg, Bad Krozingen, Berlin, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2023-11-17
Active, closed
Nektar Therapeutics
Phase 2
396
Augsburg, Erlangen, Bad Bentheim, Mainz, Leipzig, Berlin, Darmstadt, Frankfurt
2023-11-15
Recruiting
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
NCT05658640Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsTrametinib·Cytarabine·Dexamethasone·Cyclophosphamide
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2023-11-14
Active, closed
AstraZeneca
Phase 3
1,902
Augsburg, Berlin, Dessau, Dresden, Erlangen, Essen, Esslingen am Neckar, Frankfurt am Main
2023-11-14
Recruiting
MaaT Pharma
Phase 2
387
Augsburg, Berlin, Bonn, Essen, Frankfurt, Hombourg, Kiel, Leipzig
2023-10-31
Recruiting
Universität des Saarlandes
Phase 2
43
Augsburg, Erlangen, Regensburg, Mönchengladbach, Homburg
2023-10-06
Recruiting
AstraZeneca
Observational
800
Amberg, Ansbach, Apolda, Aschaffenburg, Augsburg, Bad Reichenhall, Baden-Baden, Balingen
2023-09-12
Active, closed
Janssen Research & Development, LLC
Phase 3
420
Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg
2023-08-31
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Augsburg, Berlin, Cottbus, Darmstadt, Delitzsch, Essen, Frankfurt, Frankfurt am Main
2023-08-30
Recruiting
University Hospital Freiburg
Phase 3
340
Freiburg im Breisgau, Stuttgart, Aachen, Augsburg, Berlin, Bielefeld, Bochum, Braunschweig
2023-08-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Mannheim, Augsburg, München, Göttingen, Rostock, Cologne, Essen, Minden
2023-07-19
Recruiting
Goethe University
Phase 2
220
Aachen, Aschaffenburg, Augsburg, Bad Saarow, Bayreuth, Berlin, Bielefeld, Bochum
2023-07-14
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Augsburg, Hanover, Mainz, Trier, Magdeburg, Jena, Essen
2023-07-06
Recruiting
German Cancer Research Center
Phase 2
240
Heidelberg, Tübingen, Augsburg, Erlangen, Ulm, Würzburg, Dresden, Berlin
2023-06-29
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Augsburg, Bamberg, Bendorf, Berlin, Darmstadt, Deggingen, Essen, Frankfurt
2023-06-28
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Ulm, Augsburg, Bayreuth, Erlangen, Munich, Cottbus, Hamburg, Chemnitz
2023-06-22
Recruiting
University Hospital Augsburg
Observational
300
Augsburg
2023-06-01
Active, closed
Universität des Saarlandes
Phase 2
50
Ulm, Augsburg, Erlangen, Regensburg, Frankfurt am Main, Giessen, Düsseldorf, Homburg
2023-05-25
Active, closed
Sanofi
Phase 2
999
Augsburg, Bad Bentheim, Berlin, Dresden, Münster, Osnabrück, Rostock, Witten
2023-04-03
Recruiting
AstraZeneca
Phase 3
4,300
Aachen, Augsburg, Bayreuth, Berlin, Bonn, Deggendorf, Dessau, Dresden
2023-03-31
Recruiting
Left-atrial Fibrosis in Persistent Atrial Fibrillation and Its Comorbidities
NCT07857044Atrial Fibrillation, Sleep Apnea, Primary Aldosteronism
Christina Berr. MD
Observational
200
Augsburg
2023-03-31
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Freiburg im Breisgau, Augsburg, Erlangen, Würzburg, Frankfurt am Main, Hanover, Essen, Leipzig
2023-02-27
Recruiting
University of Leipzig
Phase 4
258
Aachen, Augsburg, Berlin, Bonn, Frankfurt, Freiburg im Breisgau, Greifswald, Halle
2023-02-10
Recruiting
Acandis GmbH
Observational
153
Aschaffenburg, Augsburg, Bonn, Bremerhaven, Dresden, Duisburg, Erfurt, Halle
2023-01-25
Recruiting
Jazz Pharmaceuticals
Phase 3
510
Heidelberg, Augsburg, Regensburg, Frankfurt am Main, Bonn, Cologne, Essen, Berlin
2023-01-23
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,564
Mannheim, Tübingen, Augsburg, Erlangen, Munich, Regensburg, Darmstadt, Frankfurt am Main
2023-01-16
Active, closed
Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve
NCT05526560Mitral Stenosis, Mitral Valve Insufficiency
Edwards Lifesciences
Observational
504
Augsburg, Bad Neustadt an der Saale, Bad Oeynhausen, Bonn, Bremen, München
2023-01-11
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
Tübingen, Frankfurt am Main, Arnsberg, Leipzig, Berlin, Augsburg, Heidelberg
2023-01-06
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Augsburg, Cologne, Essen, Frankfurt, Leipzig, Munich, Münster
2023-01-05
Recruiting
GBG Forschungs GmbH
Phase 2
170
Essen, Augsburg, Berlin, Bielefeld, Chemnitz, Cologne, Dessau, Dresden
2023-01-02
Recruiting
Greenwich LifeSciences, Inc.
Phase 3
2,250
Augsburg, Bayreuth, Berlin, Bottrop, Braunschweig, Bremen, Chemnitz, Dessau
2022-12-16
Recruiting
Acandis GmbH
Observational
158
Augsburg, Berlin, Bremerhaven, Cologne, Dresden, Düsseldorf, Essen, Frankfurt am Main
2022-12-15
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Augsburg, Berlin, Bonn, Dortmund, Dresden, Erlangen, Giessen, Halle
2022-12-15
Recruiting
AstraZeneca
Phase 3
3,527
Augsburg, Berlin, Cologne, Hamburg, Hanover, Kiel, Leverkusen, Marburg
2022-12-13
Recruiting
Gilead Sciences
Phase 3
1,514
Augsburg, Berlin, Bielefeld, Bottrop, Braunschweig, Bremen, Cologne, Dortmund
2022-12-12
Active, closed
Almirall, S.A.
Phase 4
447
Augsburg, Bad Bentheim, Bochum, Bonn, Detmold, Dresden, Erlangen, Hamburg
2022-10-24
Active, closed
AbbVie
Observational
400
Heidelberg, Winnenden, Augsburg, Dachau, Munich, Brandenburg an der Havel, Potsdam, Tostedt
2022-10-20
Recruiting
Institut fuer Frauengesundheit
Phase 4
1,000
Erlangen, Mainz, Bottrop, Amberg, Aschaffenburg, Augsburg, Bamberg, Berlin
2022-10-12
Active, closed
Eli Lilly and Company
Phase 3
8,000
Augsburg, Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dortmund, Düsseldorf
2022-10-04
Recruiting
PedAL BCU, LLC
Phase 3
130
Augsburg, Berlin, Frankfurt, Münster
2022-10-01
Recruiting
AGO Study Group
Phase 3
970
Amberg, Augsburg, Bad Homburg, Berlin, Bielefeld, Brandenburg an der Havel, Bremen, Chemnitz
2022-09-13
Recruiting
Stress Reduction Using Video Googles on Patients Undergoing Vascular Surgery
NCT06704230Carotid Artery Diseases, Regional Anesthesia, Distress, Procedural
University Hospital Augsburg
Not applicable
100
Augsburg
2022-09-09
Active, closed
Sanofi
Phase 2/3
1,856
Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Dresden, Frankfurt, Gera, Hamburg
2022-08-22
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Aachen, Augsburg, Essen, Munich
2022-07-20
Active, closed
Genmab
Phase 2
264
Ulm, Augsburg, Regensburg, Würzburg, Marburg, Leipzig
2022-06-14
Active, closed
IO Biotech
Phase 3
407
Augsburg, Berlin, Bochum, Erlangen, Essen, Frankfurt, Halle, Hamburg
2022-05-17
Recruiting
Prof. Wolfgang Janni
Phase 4
300
Aalen, Amberg, Aschaffenburg, Augsburg, Berlin, Biberach, Bonn, Braunschweig
2022-04-27
Active, closed
Post-market Clinical Follow-up of the SRS Implant
NCT05170074Pelvic Organ Prolapse
pfm medical gmbh
Observational
175
Bensheim, Augsburg, Hagen, Hamburg, Kiel, Neustadt, Zittau
2022-04-07
Recruiting
University Hospital Augsburg
Observational
2,000
Augsburg
2022-04-01
Recruiting
Hoffmann-La Roche
Phase 1
332
Augsburg, Cologne, Ulm
2022-03-07
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Münster, Manheim, Mannheim, Augsburg, Berlin, Hamburg, München, Ulm
2022-03-07
Active, closed
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
NCT05153226Graft Vs Host Disease, Peripheral Blood Stem Cell Transplantation, AML, MDS
DrugCyclophosphamide
DKMS gemeinnützige GmbH
Phase 3
640
Aachen, Augsburg, Chemnitz, Cologne, Dortmund, Dresden, Düsseldorf, Essen
2022-03-02
Active, closed
Microvention-Terumo, Inc.
Observational
206
Augsburg, Bochum, Essen, Münster
2022-01-14
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Cologne, Augsburg, Berlin, Essen, Lübeck
2021-12-17
Active, closed
Joseph Broderick, MD
Phase 3
860
Heidelberg, Frankfurt am Main, Augsburg, Berlin, Tübingen
2021-12-03
Active, closed
Amgen
Phase 3
303
Augsburg, Berlin, Dresden, Düsseldorf, Heidelberg, Jena, Kiel, München
2021-11-02
Active, closed
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07280377Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
DrugsGemcitabine and nab-paclitaxel·Pelareorep·Lonsurf·Trifluridine/Tipiracil
Oncolytics Biotech
Phase 1/2
122
Heidelberg, Heilbronn, Tübingen, Ulm, Augsburg, München, Hamburg, Frankfurt am Main
2021-10-27
Active, closed
AstraZeneca
Phase 3
927
Augsburg, Berlin, Erlangen, Hamburg, Heidelberg, Kiel, Leipzig, Mönchengladbach
2021-10-25
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Karlsruhe, Augsburg, Berlin, Chemnitz, Erlangen, Essen, Georgsmarienhütte, Hamburg
2021-08-27
Recruiting
Miltenyi Biomedicine GmbH
Phase 2
213
Augsburg, Bochum, Cologne, Erlangen, Essen, Hamburg, Heidelberg, Leipzig
2021-08-18
Recruiting
German Hypoparathyroidism Registry
NCT07857460Hypoparathyroidism, Pseudohypoparathyroidism
University Hospital Augsburg
Observational
150
Augsburg
2021-07-06
Active, closed
Boehringer Ingelheim
Phase 1
554
Augsburg, Cologne, Dresden, Giessen, Oldenburg
2021-07-02
Active, closed
AstraZeneca
Phase 3
315
Ansbach, Augsburg, Bonn, Chemnitz, Dresden, Erlangen, Essen, Freiburg im Breisgau
2021-06-30
Recruiting
Corcym S.r.l
Observational
2,150
Augsburg, Bad Nauheim, Berlin, Dresden, Essen, Magdeburg, Nuremberg, Oldenburg
2021-06-29
Active, closed
The SELUTION DeNovo Study
NCT04859985Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
3,326
Augsburg, Bad Krozingen, Berlin, Bremen, Bruchsal, Cologne, Dresden, Essen
2021-05-15
Active, closed
Incyte Corporation
Phase 3
899
Aachen, Augsburg, Berlin, Bonn, Chemnitz, Cottbus, Göttingen, Halle
2021-05-11
Active, closed
AstraZeneca
Phase 3
893
Augsburg, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Georgsmarienhütte, Hanover
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Augsburg, Bad Nauheim, Berlin, Bonn, Bottrop, Dessau, Düsseldorf, Erfurt
2021-05-04
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Ulm, Augsburg, Halle, Jena, Hamburg
2021-04-09
Recruiting
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
NCT04655404High Grade Glioma, Diffuse Intrinsic Pontine Glioma
DrugLarotrectinib
Nationwide Children's Hospital
Early Phase 1
15
Heidelberg, Augsburg, Berlin, Cologne, Göttingen
2021-04-08
Recruiting
Augsburg Longitudinal Plasma Study for the Evaluation of Liquid Biopsy as Diagnostic Tool.
NCT05245136Characteristics Disease, Metastatic Cancer, Solid Tumor
University Hospital Augsburg
Observational
3,000
Augsburg
2021-03-29
Active, closed
German CLL Study Group
Phase 3
897
Augsburg, Berlin, Bremen, Cologne, Dortmund, Dresden, Düsseldorf, Eisenach
2021-03-01
Active, closed
Toralf Reimer, MD PhD
Not applicable
350
Augsburg, Baden-Baden, Berlin, Bochum, Borna, Bottrop, Böblingen, Cottbus
2021-01-13
Active, closed
Galderma R&D
Phase 3
500
Aachen, Augsburg, Bad Bentheim, Berlin, Bonn, Darmstadt, Dresden, Düsseldorf
2021-01-11
Active, closed
Amgen
Phase 1/2
181
Augsburg, Berlin, Cologne, Jena, Leipzig, Tübingen, Ulm
2021-01-04
Recruiting
Technische Universität Dresden
Not applicable
240
Mannheim, Dresden, Ansbach, Augsburg, Berlin, Bonn, Braunschweig, Dachau
2021-01-01
Active, closed
Stryker Neurovascular
Observational
405
Augsburg, Bochum
2020-12-21
Active, closed
Universität Münster
Phase 2
190
Münster, Augsburg, Bergisch Gladbach, Cologne, Duisburg, Düsseldorf, Essen, Frankfurt
2020-12-10
Active, closed
GlaxoSmithKline
Phase 2/3
758
Augsburg, Bad Berka, Berlin, Bonn, Cologne, Dresden, Essen, Frankfurt
2020-12-08
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Augsburg, Braunschweig, Dresden, Duisburg, Düesseldorf, Essen, Frankfurt am Main, Hanover
2020-12-07
Active, closed
Daiichi Sankyo
Phase 3
1,600
Augsburg, Berlin, Bielefeld, Böblingen, Braunschweig, Bremen, Chemnitz, Cologne
2020-12-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Immenstadt im Allgäu, Amberg, Augsburg, Bad Homburg, Berlin, Braunschweig, Chemnitz, Cologne
2020-12-02
Recruiting
Vyxeos® With Clofarabine for Pediatric AML
NCT07156435Relapsed Pediatric AML, Refractory Pediatric AML
DrugClofarabine
Princess Maxima Center for Pediatric Oncology
Phase 1
25
Augsburg, Berlin, Essen, Frankfurt, Hamburg
2020-11-06
Active, closed
Tyrosine Allergoid Paediatric and Adult Study
NCT05186025Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma
Allergy Therapeutics
Observational
320
Augsburg
2020-11-06
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
Heidelberg, Augsburg, Hamburg, Frankfurt am Main, Essen
2020-10-29
Active, closed
Provention Bio, a Sanofi Company
Observational
188
Bethel, Augsburg, Dresden, Hanover, Heidelberg
2020-10-26
Active, closed
German CLL Study Group
Phase 2
42
Augsburg, Cologne, Esslingen am Neckar, Hamm, Homburg, Kiel, Mönchengladbach, Munich
2020-10-01
Recruiting
Technische Universität Dresden
Phase 1/2
214
München, Essen, Aachen, Augsburg, Chemnitz, Dresden, Frankfurt am Main, Halle
2020-09-04
Recruiting
Pierre Fabre Pharma GmbH
Observational
500
Offenburg, Ulm, Augsburg, Donauwörth, Erlangen, München, Würzburg, Aschaffenburg
2020-09-03
Active, closed
Women's Cancer Study Group GmbH
Phase 3
1,260
Freiburg im Breisgau, Heilbronn, Ravensburg, Ulm, Weinheim, Baden-Baden, Tübingen, Augsburg
2020-09-02
Active, closed
AbbVie
Phase 3
330
Mannheim, Mutlangen, Augsburg, Rostock, Bochum, Chemnitz, Dresden, Hamburg
2020-08-31
Active, closed
University of Leipzig
Not applicable
5,227
München, Nuremberg, Bremen, Leipzig, Berlin, Altenburg, Aschaffenburg, Augsburg
2020-07-07
Active, closed
University Hospital, Essen
Phase 3
374
Würzburg, Rostock, Augsburg, Bochum, Dortmund, Dresden, Erfurt, Essen
2020-07-01
Recruiting
University Hospital Heidelberg
Phase 1/2
91
Augsburg, Berlin, Essen, Hanover, Heidelberg
2020-05-26
Active, closed
Galderma R&D
Phase 3
1,700
Aachen, Augsburg, Bad Bentheim, Berlin, Bielefeld, Bonn, Buxtehude, Darmstadt
2019-12-30
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Augsburg, Berlin, Chemnitz, Freiburg im Breisgau, Göttingen, Lingen, Münster, Tübingen
2019-12-17
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Cologne, Augsburg, Berlin, Essen, Hamburg
2019-11-04
Recruiting
Pierre Fabre Pharma GmbH
Observational
750
Ahaus, Aschaffenburg, Augsburg, Berlin, Bremerhaven, Buxtehude, Chemnitz, Donauwörth
2019-10-17
Recruiting
University Hospital Muenster
Phase 3
683
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Bremen, Chemnitz
2019-08-23
Recruiting
COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer
NCT05906407Early-Stage Breast Cancer, Neoadjuvant Therapy
German Cancer Research Center
Observational
2,000
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg
2019-04-19
Active, closed
Evidence For Fusion In Spine With Orthoss®
NCT03853356Lumbar Spondylolisthesis Involving L4-L5, Lumbar Spondylolisthesis Involving L5-S1, Lumbar Spinal Stenosis, Lumbar Disc Degeneration
Geistlich Pharma AG
Observational
65
Augsburg, Düsseldorf, Magdeburg
2019-01-18
Active, closed
AbbVie
Phase 2
270
Mannheim, Augsburg, Giessen, Kassel, Oldenburg, Halle, Berlin, Gauting
2018-10-10
Active, closed
Ipsen
Observational
224
Aachen, Aschaffenburg, Augsburg, Bad Homburg, Bad Liebenwerda, Bad Schlema, Bamberg, Bergisch Gladbach
2018-09-24
Active, closed
Wuerzburg University Hospital
Phase 3
576
Freiburg im Breisgau, Mutlangen, Ravensburg, Stuttgart, Ulm, Villingen-Schwenningen, Amberg, Augsburg
2018-08-28
Active, closed
University Hospital Tuebingen
Phase 3
1,065
Amberg, Augsburg, Bad Kreuznach, Bremen, Dresden, Düsseldorf, Erfurt, Esslingen am Neckar
2018-07-27
Recruiting
Martin Schrappe
Phase 3
5,000
Aachen, Augsburg, Berlin, Braunschweig, Chemnitz, Cologne, Cottbus, Datteln
2018-07-15
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Augsburg, Berlin, Dresden, Frankfurt, Frankfurt am Main, Hamburg, Hanover, Heidelberg
2018-04-13
Recruiting
Endometrial Cancer Lymphadenectomy Trial
NCT03438474Cancer of Endometrium Stage I, Cancer of Endometrium Stage II
Philipps University Marburg
Not applicable
640
Aalen, Amberg, Ansbach, Augsburg, Bad Homburg, Bamberg, Berlin, Bonn
2018-03-28
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Mannheim, Augsburg, Berlin, Essen, Hamburg, Heidelberg
2018-01-26
Recruiting
AbbVie
Observational
500
Mutlangen, Stuttgart, Villingen-Schwenningen, Aschaffenburg, Augsburg, Bad Reichenhall, Erlangen, Hof
2017-12-04
Active, closed
University Hospital Muenster
Phase 3
650
Aachen, Augsburg, Berg, Berlin, Bielefeld, Bonn, Braunschweig, Bremen
2017-08-03
Recruiting
Prospective Endoscopic Follow-up of Patients With Submucosal and High Risk Mucosal Esophageal Adenocarcinoma
NCT03222635Submucosal Esophageal Adenocarcinoma, Barrett Esophagus, High-risk Mucosal Esophageal Adenocarcinoma
Amsterdam UMC
Not applicable
225
Augsburg, Düsseldorf, Münich, Regensburg
2017-07-25
Active, closed
Eli Lilly and Company
Phase 3
5,637
Freiburg im Breisgau, Friedrichshafen, Ludwigsburg, Tübingen, Ulm, Amberg, Augsburg, Erlangen
2017-07-12
Recruiting
German Cancer Research Center
Observational
5,000
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Heidelberg, Regensburg
2017-06-12
Active, closed
Persona Partial Knee Clinical Outcomes Study
NCT03034811Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Conditional Tibial Condyle or Plateau Fractures
Zimmer Biomet
Not applicable
757
Augsburg, Berlin, Eisenberg
2017-02-08
Active, closed
Universitätsmedizin Mannheim
Phase 3
314
Augsburg, Berlin, Leipzig, Mannheim, Munich, Stuttgart, Wuppertal
2016-12-09
Recruiting
Neurovascular Product Surveillance Registry
NCT02988128Intracranial Aneurysm, Stroke, Ischemic
Medtronic Neurovascular Clinical Affairs
Observational
4,000
Augsburg, Berlin, Bochum, Erfurt, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2016-12
Active, closed
Philogen S.p.A.
Phase 3
214
Dresden, Hanover, Heidelberg, Kiel, Leipzig, Berlin, Tübingen, Augsburg
2016-07-01
Recruiting
International HIT-MED Registry (I-HIT-MED)
NCT02417324Childhood Brain Tumor
Universitätsklinikum Hamburg-Eppendorf
Observational
500
Aachen, Augsburg, Berlin, Bielefeld, Braunschweig, Bremen, Chemnitz, Cologne
2015-01
Active, closed
Eli Lilly and Company
Phase 3
669
Ludwigsburg, Tübingen, Augsburg, München, Hamburg
2014-07-22
Active, closed
Universitätsklinikum Hamburg-Eppendorf
Phase 2/3
360
Aachen, Augsburg, Berlin, Bielefeld, Bonn, Braunschweig, Bremen, Chemnitz
2014-06
Active, closed
AstraZeneca
Phase 3
1,837
Aachen, Augsburg, Baden-Baden, Berlin, Bonn, Bottrop, Brandenburg, Bremen
2014-04-22
Active, closed
AstraZeneca
Phase 3
510
Augsburg, Bad Berka, Cologne, Dortmund, Gerlingen, Großhansdorf, Halle, Heidelberg
2013-09-25
Recruiting
University of Ulm
Observational
2,172
Augsburg, Bad Saarow, Baden-Baden, Coburg, Donauwörth, Dresden, Erding, Freiburg im Breisgau
2013-05
Recruiting
German Asthma Net e.V.
Observational
4,500
Altdorf, Augsburg, Bad Windsheim, Bamberg, Berlin, Bielefeld, Bonn, Böblingen
2011-11-01
Recruiting
Technische Universität Dresden
Observational
15,000
Baden-Baden, Heidelberg, Mannheim, Schwäbisch Hall, Sindelfingen, Stuttgart, Winnenden, Augsburg
2010-09
Recruiting
University of Ulm
Observational
50,000
Aschaffenburg, Augsburg, Aurich, Bad Saarow, Berlin, Bochum, Bonn, Braunschweig
2010-07-06
Recruiting
Goethe University
Observational
10,000
Frankfurt am Main, Aachen, Altenburg, Altötting, Aschaffenburg, Augsburg, Bad Saarow, Bamberg
2009-02
Rows per page Showing 1–251 of 251
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 14 October 2026. https://priyalifescience.com/clinical-trials-germany/city/augsburg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,060 studies in total at the last sync on 14 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 251 of those studies with a site in Augsburg.

How many clinical trials are recruiting in Augsburg?

149 of the 251 studies on this page are recruiting new participants as of the 14 Oct 2026, 03:18 UTC sync. A further 6 have not yet opened recruitment, 94 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Augsburg), 251 studies
PhaseStudiesRecruitingShare
Phase 3984339%
Observational554321.9%
Phase 2392415.5%
Not applicable271810.8%
Phase 1/21084%
Phase 41064%
Phase 2/3732.8%
Phase 1431.6%
Early Phase 1110.4%

Most active sponsors

Lead sponsors with the most studies (Augsburg)
Lead sponsorStudiesRecruiting
AstraZeneca2012
University Hospital Augsburg1411
AbbVie74
Janssen Research & Development, LLC71
Novartis Pharmaceuticals73
Sanofi74
Eli Lilly and Company51
Princess Maxima Center for Pediatric Oncology55
Technische Universität Dresden55
Women's Cancer Study Group GmbH53
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.